Arcus Biosciences, Inc.

NYSE:RCUS Stock Report

Market Cap: US$1.6b

Arcus Biosciences Future Growth

Future criteria checks 2/6

Arcus Biosciences is forecast to grow earnings and revenue by 12% and 22.5% per annum respectively. EPS is expected to grow by 17% per annum. Return on equity is forecast to be -94.1% in 3 years.

Key information

12.0%

Earnings growth rate

17.0%

EPS growth rate

Biotechs earnings growth29.0%
Revenue growth rate22.5%
Future return on equity-94.1%
Analyst coverage

Good

Last updated19 Aug 2024

Recent future growth updates

Recent updates

Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Sep 15
Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business

Aug 19
Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business

Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31
Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO

May 15

Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

May 13
Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

May 10
Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

Mar 20
We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Feb 23
What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment

Feb 22

Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Dec 18
Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Arcus Biosciences: Showing There Might Be Something To TIGIT After All

Dec 15

Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Nov 30
Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey

Nov 20

Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data

Aug 29

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Aug 08
Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates

Jun 15

Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

May 05
Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17

Nov 02

Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers

May 12
Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers

Earnings and Revenue Growth Forecasts

NYSE:RCUS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026286-358-142-797
12/31/2025193-447-446-6238
12/31/2024271-281-175-2678
6/30/2024247-249-267-247N/A
3/31/2024237-231-235-210N/A
12/31/2023117-307-330-306N/A
9/30/2023120-293-306-288N/A
6/30/2023121-287-316-306N/A
3/31/2023119-279-326-314N/A
12/31/2022112-267426438N/A
9/30/202243380426446N/A
6/30/202240967447473N/A
3/31/202239258439464N/A
12/31/202138353-282-256N/A
9/30/202138-278-263-244N/A
6/30/202193-1991426N/A
3/31/202185-1687076N/A
12/31/202078-123108111N/A
9/30/202078-88150152N/A
6/30/202015-112-93-92N/A
3/31/202015-95-89-88N/A
12/31/201915-85-75-73N/A
9/30/20197-80-73-71N/A
6/30/20199-69-58-55N/A
3/31/20199-54-50-47N/A
12/31/20188-50-47-43N/A
9/30/20188-51-24-20N/A
6/30/20184-63-36-33N/A
3/31/20183-59N/A-29N/A
12/31/20171-53N/A-25N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RCUS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RCUS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RCUS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RCUS's revenue (22.5% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: RCUS's revenue (22.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RCUS is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y